• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Natural Alternatives International, Inc. Announces 2022 Q1 Results

    11/9/21 4:30:00 PM ET
    $NAII
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $NAII alert in real time by email

    CARLSBAD, Calif., Nov. 9, 2021 /PRNewswire/ -- -Natural Alternatives International, Inc. ("NAI") (NASDAQ:NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced net income of $3.3 million, or $0.51 per diluted share, on net sales of $38.3 million for the first quarter of fiscal year 2022 compared to net income of $2.3 million, or $0.35 per diluted share, in the first quarter of the prior fiscal year. 

    Net sales during the three months ended September 30, 2021 decreased $1.4 million, or 3.5%, to $38.3 million as compared to $39.7 million recorded in the comparable prior year period.  During the same period, private-label contract manufacturing sales decreased to $33.6 million, a 9.3% decrease from the comparable quarter last year. Private-label contract manufacturing sales decreased primarily due to a 45% decrease in sales to our largest customer primarily associated with their European markets. This sales decline was largely offset by  increased sales to new and existing customers including significant sales from a new customer operating in the direct-to-consumer marketplace. Sales backlog for the quarter ended September 30, 2021 exceeded $8.0 million and was primarily related to supply chain and logistical constraints.

    CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue increased 77.1% to $4.7 million during the first quarter of fiscal year 2022, as compared to $2.7 million for the first quarter of fiscal year 2021. The increase in patent and trademark licensing revenue during the first quarter of fiscal 2022 was primarily due to increased shipments to existing customers related to athletic activities and gyms reopening in accordance with easing COVID-19 restrictions across the USA as compared to significant restrictions in athletic activities in the first quarter of fiscal 2021 combined with sales to new customers and higher average sales prices.

    Based on our current sales order volumes, backlog and forecasts we have received from our customers; we now anticipate our fiscal year 2022 consolidated net sales will increase between 7.0% and 10.0% as compared to fiscal year 2021. We also now anticipate we will generate operating income between 10.0% and 13.0% of net sales for our fiscal year ending June 30, 2022. Sales and profitability during the first half of fiscal 2022 are anticipated to decline when compared to the same period of fiscal 2021. Our expectations for the first half of fiscal 2022 are being driven by continuing supply chain, labor, and logistical constraints, all of which are expected to result in a backlog of existing orders that may not be fully cleared until the second half of fiscal 2022. We currently anticipate these supply chain and manufacturing challenges will mostly resolve themselves during the second half of fiscal 2022. As a result, we expect sales and profitability in the second half of fiscal 2022 to exceed the comparable period in fiscal 2021, with the overall fiscal 2022 results reflecting an increase in both sales and profitability on a full year basis.

    As of September 30, 2021, we had cash of $20.0 million and working capital of $54.6 million compared to $32.1 million and $58.3 million respectively, as of June 30, 2021. As of September 30, 2021, we had $20.0 million available under our line of credit agreement.

    Mark A. Le Doux, Chairman and Chief Executive Officer of NAI stated, "Despite a decline in sales from our largest customer, we have been able to make significant progress in growing our business with other customers in a variety of channels, including the recent acquisition of a new direct to consumer based customer we expect will help drive significant future growth for our company.  We believe the dietary supplement industry is in a period of meaningful growth, and we find ourselves in the enviable position where we are able to capitalize on new opportunities leveraging our reputation of quality and integrity along with our available equipment capacity supported by the strength of our balance sheet."

    "We continue to navigate challenges related to supply chain and staffing that have resulted in larger than normal backlog, but we believe we will be able to overcome these challenges by the end of this calendar year. Our investments related to securing adequate supplies of inventory and labor are expected to pay dividends in the second half of our current fiscal year."

    "We believe our favorable profitability as a percentage of sales is a trend that will be fully realized on a full year basis supported by improved customer mix, capacity utilization, favorable currency translation on foreign sales, and improved contribution from our CarnoSyn® business."

    An updated investor presentation will be posted to the investor relations page on our website later today (https://www.nai-online.com/our-company/investors/).

    NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers.  Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at http://www.nai-online.com.

    This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information.  These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our ability to develop, maintain or increase sales to new and existing customers, our ability to attract and retain sufficient labor, COVID-19 and related impacts on the availability of raw materials, our future revenue profits and financial condition, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein.  NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks, including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.

    CONTACT – Michael Fortin, Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or [email protected].

    Web site: http://www.nai-online.com

    NATURAL ALTERNATIVES INTERNATIONAL, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF INCOME

    (In thousands, except per share data)





    (Unaudited)









    Three Months Ended









    September 30, 









    2021







    2020







    NET SALES

    $     38,340



    100.0%



    $     39,726



    100.0%



    Cost of goods sold

    30,059



    78.4%



    33,721



    84.9%



    Gross profit

    8,281



    21.6%



    6,005



    15.1%





















    Selling, general & administrative expenses

    4,053



    10.6%



    3,920



    9.9%





















    INCOME FROM OPERATIONS

    4,228



    11.0%



    2,085



    5.2%





















    Other expense, net

    (26)



    -0.1%



    (321)



    -0.8%



    INCOME BEFORE TAXES

    4,202



    11.0%



    1,764



    4.4%





















    Income tax expense (benefit)

    946







    (494)

























    NET INCOME

    $      3,256







    $      2,258











































    NET INCOME PER COMMON SHARE:

















    Basic:

    $0.52







    $0.35

























    Diluted:

    $0.51







    $0.35

























    WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:

















    Basic

    6,288







    6,418







    Diluted

    6,351







    6,471

























    NATURAL ALTERNATIVES INTERNATIONAL, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (In thousands)











    (unaudited)







    September 30,



    June 30,



    2021



    2021









    ASSETS







    Cash and cash equivalents

    $20,028



    $32,133

    Accounts receivable, net

    20,245



    17,946

    Inventories, net

    31,709



    27,006

    Other current assets

    3,254



    3,263

        Total current assets

    75,236



    80,348

    Property and equipment, net

    39,504



    22,271

    Operating lease right-of-use assets

    15,212



    15,877

    Other noncurrent assets, net

    2,211



    1,785

        Total Assets

    $132,163



    $120,281









    LIABILITIES AND STOCKHOLDERS' EQUITY







    Accounts payable and accrued liabilities

    21,921



    23,717

    Line of credit

    10,000



    -

    Long-term liability - operating leases

    15,737



    16,481

        Total Liabilities

    47,658



    40,198

    Stockholders' Equity

    84,505



    80,083

        Total Liabilities and Stockholders' Equity

    $132,163



    $120,281









    Cision View original content:https://www.prnewswire.com/news-releases/natural-alternatives-international-inc-announces-2022-q1-results-301420305.html

    SOURCE Natural Alternatives International, Inc.

    Get the next $NAII alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NAII

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NAII
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Natural Alternatives International, Inc. Announces Fiscal 2025 Q4 and YTD Results

    CARLSBAD, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (NASDAQ:NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $7.2 million, or ($1.20) per diluted share, on net sales of $33.9 million for the fourth quarter of fiscal year 2025 compared to a net loss of $1.9 million, or ($0.32) per diluted share, in the fourth quarter of the prior fiscal year. Our net loss for the fourth quarter of fiscal 2025 included non-recurring non-cash charges of $1.4 million related to the settlement of a litigation matter and a $4.8 million valuation allowance against our net deferred tax asse

    9/23/25 4:30:00 PM ET
    $NAII
    Medicinal Chemicals and Botanical Products
    Health Care

    Natural Alternatives International, Inc. Announces New Manufacturing Agreement with The Juice Plus+® Company

    CARLSBAD, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (NASDAQ:NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced it has extended its partnership with The Juice Plus+ Company ("Juice Plus+"), a globally recognized leader in plant-based whole-body nutritional products, through the execution of a new multi-year Manufacturing Agreement covering Juice Plus+ capsule and powder products sold in over 24 markets around the world. Mark A. LeDoux, NAI's CEO and Chairman of the Board, said, "Continuing our 30+ year relationship with JuicePlus+ reflects our shared commitment to delivering premium nutrit

    7/21/25 4:30:00 PM ET
    $NAII
    Medicinal Chemicals and Botanical Products
    Health Care

    Natural Alternatives International, Inc. Announces Amended and Extended Credit Facility with Wells Fargo Bank

    CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (NASDAQ:NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced the execution of an amended credit facility with Wells Fargo Bank, NA ("Wells Fargo"). This amendment modifies the current facility extending the term of the agreement to December 31, 2026 and modifies the borrowing capacity to $10 million. Mark A. Le Doux, Chairman and Chief Executive Officer of NAI stated, "We are grateful for our long-standing relationship with Wells Fargo and we believe this amended credit facility is made possible by the strength of our balance sheet.

    6/23/25 4:15:43 PM ET
    $NAII
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAII
    SEC Filings

    View All

    SEC Form 10-K filed by Natural Alternatives International Inc.

    10-K - NATURAL ALTERNATIVES INTERNATIONAL INC (0000787253) (Filer)

    9/23/25 4:16:24 PM ET
    $NAII
    Medicinal Chemicals and Botanical Products
    Health Care

    Natural Alternatives International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NATURAL ALTERNATIVES INTERNATIONAL INC (0000787253) (Filer)

    7/21/25 4:32:50 PM ET
    $NAII
    Medicinal Chemicals and Botanical Products
    Health Care

    Natural Alternatives International Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - NATURAL ALTERNATIVES INTERNATIONAL INC (0000787253) (Filer)

    7/1/25 4:01:11 PM ET
    $NAII
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dunn Alan G was granted 8,000 shares, increasing direct ownership by 10% to 91,211 units (SEC Form 4)

    4 - NATURAL ALTERNATIVES INTERNATIONAL INC (0000787253) (Issuer)

    3/11/25 5:16:26 PM ET
    $NAII
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Ramanathan Guru was granted 8,000 shares, increasing direct ownership by 36% to 30,000 units (SEC Form 4)

    4 - NATURAL ALTERNATIVES INTERNATIONAL INC (0000787253) (Issuer)

    3/11/25 5:15:28 PM ET
    $NAII
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Matherly Laura Kay was granted 8,000 shares, increasing direct ownership by 31% to 34,000 units (SEC Form 4)

    4 - NATURAL ALTERNATIVES INTERNATIONAL INC (0000787253) (Issuer)

    3/11/25 5:15:06 PM ET
    $NAII
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAII
    Leadership Updates

    Live Leadership Updates

    View All

    Natural Alternatives International Appoints New VP of Global Sales

    CARLSBAD, Calif., July 25, 2023 /PRNewswire/ -- Natural Alternatives International, Inc. ("NAI") (NASDAQ:NAII) ), a leading formulator, manufacturer, and marketer of customized nutritional supplements, announced that sales executive Shane Conti has joined the company as the Vice President of Global Sales and will be a key driver of global expansion and growth. Over the course of his 25 plus year career in the domestic and international nutritional supplement industry, Conti has established a proven track record of success in building new business within multiple markets. "Shan

    7/25/23 9:00:00 AM ET
    $NAII
    Medicinal Chemicals and Botanical Products
    Health Care

    NATURAL ALTERNATIVES INTERNATIONAL APPOINTS AARON STARR VICE PRESIDENT FOR CARNOSYN® BRANDS

    CARLSBAD, Calif., April 21, 2022 /PRNewswire/ -- Natural Alternatives International, Inc. ("NAI") (NASDAQ:NAII), an international leader in custom contract nutritional supplement manufacturing for over four decades, announced Aaron Starr has been promoted to Vice President of CarnoSyn® Brands. In his new role, Starr will be responsible for the leadership of business teams and for overseeing operational performance and the advancement of CarnoSyn® Brands. "I am pleased to announce Aaron Starr has been named Vice President of CarnoSyn® Brands," said Kenneth Wolf, President and Chief Operating Officer, Natural Alternatives International. "Aaron has been a valued member of our team for many year

    4/21/22 5:00:00 PM ET
    $NAII
    Medicinal Chemicals and Botanical Products
    Health Care

    Neptune Wellness Appoints Randy Weaver as Interim Chief Financial Officer and Retains Dr. Toni Rinow as Chief Operating Officer

    LAVAL, QC, Sept. 27, 2021 /PRNewswire/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT) (TSX:NEPT), a diversified and fully integrated health and wellness company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced the appointment of Randy Weaver as Interim Chief Financial Officer while retaining Dr. Toni Rinow as Chief Operating Officer. Mr. Weaver joins Neptune as Interim Chief Financial Officer with a successful track record of leading numerous CPG companies as a senior executive, bringing the knowledge and e

    9/27/21 7:30:00 AM ET
    $NAII
    $NEPT
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $NAII
    Financials

    Live finance-specific insights

    View All

    Natural Alternatives International, Inc. Announces 2022 Q1 Results

    CARLSBAD, Calif., Nov. 9, 2021 /PRNewswire/ -- -Natural Alternatives International, Inc. ("NAI") (NASDAQ:NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced net income of $3.3 million, or $0.51 per diluted share, on net sales of $38.3 million for the first quarter of fiscal year 2022 compared to net income of $2.3 million, or $0.35 per diluted share, in the first quarter of the prior fiscal year.  Net sales during the three months ended September 30, 2021 decreased $1.4 million, or 3.5%, to $38.3 million as compared to $39.7 million recorded in the comparable prior year period.  During the same period, private-label contract man

    11/9/21 4:30:00 PM ET
    $NAII
    Medicinal Chemicals and Botanical Products
    Health Care

    Natural Alternatives International, Inc. Announces 2021 Q3 and YTD Results

    CARLSBAD, Calif., May 13, 2021 /PRNewswire/ -- Natural Alternatives International, Inc. ("NAI") (NASDAQ:NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $1.9 million, or $0.30 per diluted share, on net sales of $46.3 million for the third quarter of fiscal year 2021 compared to a net loss of $4.0 million, or $0.61 per diluted share, in the third quarter of the prior fiscal year.  Our results for the third quarter of fiscal 2020 included the negative impact of a $4.3 million accounts receivable and inventory reserve related to a former customer, which was not repeated in the third quarter of fiscal 2021.  Net s

    5/13/21 4:30:00 PM ET
    $NAII
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Natural Alternatives International Inc. (Amendment)

    SC 13G/A - NATURAL ALTERNATIVES INTERNATIONAL INC (0000787253) (Subject)

    2/13/24 10:37:08 AM ET
    $NAII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Natural Alternatives International Inc. (Amendment)

    SC 13G/A - NATURAL ALTERNATIVES INTERNATIONAL INC (0000787253) (Subject)

    2/9/24 9:59:14 AM ET
    $NAII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Natural Alternatives International Inc. (Amendment)

    SC 13G/A - NATURAL ALTERNATIVES INTERNATIONAL INC (0000787253) (Subject)

    2/5/24 8:25:38 PM ET
    $NAII
    Medicinal Chemicals and Botanical Products
    Health Care